Hard to value IP, especially when the company's not traded on a legitimate exchange. The real question is what will LP take if she's serious about selling.
From a spec perspective, it looks very interesting in that it could become SOC.
From big pharmas view, you can't keep it or sell it for very much if you cannot demonstrate the ability to profitably manufacture the product and take it to market.
On a stand alone basis, this tug of war could continue for a long time. The big boys will keep the SP low so that continued financings will eventually dilute the shareholders into oblivion. The big boys understand this, that's why they are big and Northwest is small!!!
LP's best option is to continue pressing for UK approval If successful, the UK model becomes a work in progress that can be replicated in other jurisdictions and by pointing to the UK RA, reduces the high hurdles presently applied by the US FDA and others.This strategy might allow Northwest to keep it all !!!, but at what cost regarding the time value of money.
We all know what the other options are: Partnership for the whole ball of wax, targeted asset sales trying to net enough to finance the next DCVax product..... all the while trying to convince the analysts that management can continue to pull the rabbit out of the hat. and continue to beat the slightly prejudiced regulators at every turn AND somehow keep the ever advancing technologies from displacing DCVax like DCVax is threatening to replace them.
One thing's for sure, it's a brutal game and LP's doing everything she can to win!!! If she does, I think she deserves to be named the permanent Queen/ruler of healthcare treatments for all humankind and the creator of an affordable healthcare system that works for everyone, not just the wealthy
Cheers and Happy New Year.
BB
Market Data 
Markets 
AI
